Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Chokri Ben Lamine: Choosing the Right LMWH in Cancer Patients
Chokri Ben Lamine/X
Apr 23, 2026, 18:19

Chokri Ben Lamine: Choosing the Right LMWH in Cancer Patients

Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:

”LMWH Showdown: Enoxaparin versus Dalteparin versus Tinzaparin (Adult Heme/Onc)

Core Concept

All are LMWH with anti-Xa dominant (via AT-III)

Differences include PK, dosing frequency, evidence in cancer-associated thrombosis (CAT)

1) Enoxaparin

Most widely used

Dosing (treatment):

  • 1 mg/kg SC q12h (preferred in cancer)
  • or 1.5 mg/kg SC daily

Renal:

CrCl less than 30 – 1 mg/kg daily

Monitoring:

Anti-Xa (target approximately 0.6–1.0 IU/mL q12h)

Outcomes:

  • Strong historical standard (CLOT comparator era)
  • Higher GI bleeding versus DOACs in some data
  • Excellent VTE prevention

2) Dalteparin

Gold standart in cancer trials

Dosing (CLOT trial):

  • 200 IU/kg daily – 1 month
  • Then 150 IU/kg daily

Renal:

Safer in CKD vs enoxaparin (less accumulation)

Outcomes:

  • reduced recurrent VTE versus warfarin (CLOT trial landmark)
  • Lower bleeding versus VKAs
  • Longest evidence in malignancy-associated thrombosis

3) Tinzaparin

Underrated but VERY strong in cancer

Dosing:

175 IU/kg SC daily

Renal:

Least accumulation preferred in CrCl less than 30–20

Outcomes:

  • CATCH trial – similar VTE recurrence versus warfarin
  • LOWER clinically relevant non-major bleeding
  • Favorable safety in elderly/renal impairment

Head-to-Head Practical Differences

Frequency:

  • Enoxaparin – BID or OD
  • Dalteparin – OD
  • Tinzaparin – OD

Renal safety:

  • Tinzaparin
  • Dalteparin
  • Enoxaparin

Cancer evidence:

  • Dalteparin (clot)
  • Tinzaparin (catch)
  • Enoxaparin (extensive real-world)

Anti-Xa predictability:

  • Tinzaparin is greater than Dalteparin, and Dalteparin is greater than Enoxaparin.

Cancer-Associated Thrombosis (CAT)

LMWH still preferred when:

  • High bleeding risk (GI/GU tumors)
  • Drug interactions (DOAC limitation)
  • Post-BMT / thrombocytopenia

Dose Adjustments (critical)

Platelets:

  • 50 – full dose
  • 25–50 – 50% dose
  • less than 25 – Hold

Obesity:

  • Use actual body weight (no cap)

Anti-Xa monitoring:

  • Required in extremes (obesity, pregnancy, renal)

Toxicities

  • Bleeding
  • HIT (rare versus UFH)
  • Osteoporosis (long-term)

Expert Pearls

  • Enoxaparin BID superior to OD in cancer
  • Tinzaparin – best in renal failure
  • Dalteparin – most guideline-backed in oncology
  • Switch to DOAC only if bleeding risk LOW

MCQ

Cancer patient with CrCl 25 ml/min, VTE – best LMWH?

  1. Enoxaparin BID
  2. Dalteparin
  3. Tinzaparin
  4. Fondaparinux

Answer: C (Tinzaparin – least renal accumulation)

OSCE Scenario

Metastatic pancreatic cancer plus new PE

  • Start dalteparin 200 IU/kg daily
  • Reassess bleeding risk
  • Continue at least 6 months.”

Stay updated with Hemostasis Today.

bleeding Chokri Ben Lamine dalteparin Enoxaparin Health Hematology Hemostasis Hemostasis News Hemostasis Today LMWH Medicine thrombosis Tinzaparin
NewsFeed